Related content

Antagonists of TNF action: clinical experience and new developments

By Kontermann Roland E   Scheurich Peter   Pfizenmaier Klaus  

Expert Opinion on Drug Discovery, Vol. 4, Iss. 3, 2009-03 ,pp. : 279-292

Informa Healthcare

Access to resources Recommend Favorite

Interferon-Beta in the Treatment of Multiple Sclerosis: Do Clinical Data Support the Existence of a Ceiling Effect?

By Clanet M.  

Clinical Drug Investigation, Vol. 21, Iss. 4, 2001-04 ,pp. : 307-318

Adis International

Access to resources Recommend Favorite

Drugs in Clinical Development for Multiple Sclerosis: Summary and Table

By  

Pharmaceutical Medicine, Vol. 26, Iss. 2, 2012-04 ,pp. : 103-112

Adis International

Access to resources Recommend Favorite

Multiple Sclerosis In Childhood and Adolescence: Clinical Features and Management

By Pinhas-Hamiel O.   Sarova-Pinhas I.   Achiron A.  

Pediatric Drugs, Vol. 3, Iss. 5, 2001-01 ,pp. : 329-336

Adis International

Access to resources Recommend Favorite

Recent Gains in Clinical Multiple Sclerosis Research

By  

CNS & Neurological Disorders - Drug Targets (Formerly Current Drug Targets - CNS & Neurological Disorders), Vol. 11, Iss. 5, 2012-08 ,pp. : 497-505

Bentham Science Publishers

Access to resources Recommend Favorite